375PD - A validation study of a new point-of-care nerve conduction device for the quantitative assesment of chemotherapy-induced peripheral neurotoxicity

Date 21 December 2015
Event ESMO Asia 2015 Congress
Session Supportive and palliative care
Topics Complications of Treatment
Supportive Care
Presenter Ayumu Matsuoka
Citation Annals of Oncology (2015) 26 (suppl_9): 111-124. 10.1093/annonc/mdv531
Authors A. Matsuoka1, A. Mitsuma2, O. Maeda2, K. Uehara3, T. Kikumori4, H. Kajiyama5, H. Kiyoi6, Y. Kodera7, Y. Ando2
  • 1Clinical Oncology And Chemotherapy, Nagoya University Hospital, 466-8550 - Nagoya/JP
  • 2Clinical Oncology And Chemotherapy, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 3Surgical Oncology, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 4Breast And Endocrine Surgery, Nagoya University Hospital, 466-8550 - Nagoya/JP
  • 5Obstetrics And Gynecology/reproductive Oncology, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 6Hematology And Oncology, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 7Gastroenterological Surgery (surgery â…¡), Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP

Abstract

Aim/Background

Chemotherapy-induced peripheral neurotoxicity (CIPN) seriously deteriorates patient's QOL. CIPN worsens in a cumulative dose-dependent manner and is often the major dose-limiting toxicity for many anticancer agents. Assessment of CIPN usually depends on subjective evaluation using a semi-quantitative scale, NCI-CTCAE. We prospectively assessed CIPN using a newly-developed point-of-care nerve conduction device (POCD).

Methods

Patients who were undergoing chemotherapy and clinically diagnosed CIPN of grade (G) 1 or worse according to NCI-CTCAE were evaluated for sural nerve amplitude potentials (SNAP, &mgr;V), a quantitative measure of the axonal degeneration, and sural nerve conduction velocity (SNCV, m/s), that of the degree of demyelination, using a portable and automated POCD (DPN-Check®, Neurometrix Inc.) that has been validated for the assessment of diabetic peripheral neuropathy. The SNAP/SNCV were compared with the reference from normal population, as well as the toxicity grade.

Results

A total of 50 patients (G1/G2/G3: 21/18/11) were enrolled. Patients were; male/female: 22/28; median age 64 (34-85); cancer origin: colon in 13 pts, breast 8, gastric 5, pancreas 5, gynecology 5, hematology 7 and others 7; responsible drugs (median cumulative dose): paclitaxel in 16 pts (3,315 mg), docetaxel 14 (517.5 mg), oxaliplatin 15 (1,020 mg), bortezomib 3 (171 mg), vincristine 6 (8 mg), nab-paclitaxel 7 (1,400 mg), and cisplatin 5 (300 mg). Mean SNAP were 8.45 ± 3.67 in those with G1 CIPN, 5.41 ± 2.68 G2, and 2.45 ± 1.52 G3. Mean SNCV were 49.71 ± 4.77 G1, 48.74 ± 6.33 G2, and 44.14 ± 7.31 G3. The SNAP of the patients with G2 or worse were significantly lower than the reference (p = 0.010), whereas the SNCV from those studied were similar to the reference. The SNAP had negatively correlated with the CTCAE grade (r= -0.685, p< 0.0001).

Conclusions

The POCD was validated to be effective for quantitative assessment of CIPN.

Clinical trial identification

UMIN000016505

Disclosure

All authors have declared no conflicts of interest.